State by state.
Every U.S. state and DC, with direct links to the medical and pharmacy boards that actually regulate peptide therapy. Where we have cited evidence of an enforcement pattern, we add an editorial note.
Educational reference, not legal advice. Regulatory landscapes change. Always confirm current rules with the named agency or a licensed attorney in the relevant state.
Click a state
Each state is colored by its current regulatory posture toward peptide therapy. Tap or click a state to see its medical board, pharmacy board, and any cited enforcement notes.
States with TPC editorial notes
Sorted by category. Each card links to a detailed page with cited sources, agency links, and last-reviewed date.
California
Aggressive enforcement against unlicensed peptide prescribing. The Medical Board of California has issued multiple cease-and-desist letters since 2023 to wellness clinics dispensing peptides without a documented in-person evaluation. AB-2098 (effective 2023) tightened the telehealth standard-of-care framework that governs initial encounters.
Massachusetts
Restrictive. Following the 2012 NECC meningitis outbreak — which originated at a Massachusetts compounding pharmacy — the state imposed the strictest 503A oversight regime in the country. Inspection frequency, complaint review, and disciplinary action rates exceed national averages.
New York
Restrictive. The New York State Office of the Professions oversees professional discipline through the State Education Department — an unusual structure that has historically meant slower but stricter enforcement. New York's Section 6530 (definitions of professional misconduct) is broad and has been applied to peptide prescribing cases.
Colorado
Moderate. The Colorado Medical Board and Pharmacy Board have not visibly targeted peptide compounding, but Colorado generally follows USP guidance closely and out-of-state mail-order compounding is monitored.
Tennessee
Tennessee Practice of Medicine Act, Tenn. Code Ann. § 63-6-204, prohibits diagnosis or treatment without a valid provider-patient relationship — the statute The Peptide Column's own legal disclaimers reference. Telehealth permitted under Tenn. Code Ann. § 63-1-155 but requires an established relationship for prescribing controlled substances.
Washington
Moderate. Washington State Medical Commission has not pursued visible peptide-targeted enforcement. The state Pharmacy Quality Assurance Commission follows USP guidance with state additions.
Arizona
Permissive jurisdiction with established compounding infrastructure. Arizona Medical Board has issued occasional disciplinary actions but no broad pattern of peptide-targeted enforcement. Strong 503A presence.
Florida
Permissive. Large concentration of anti-aging and wellness clinics offering peptide therapies. The Florida Board of Medicine has not pursued the visible enforcement pattern seen in California or New York. Telehealth was expanded under HB 23 (2019).
Nevada
Permissive. Wellness and anti-aging clinic concentration in Las Vegas. Nevada State Board of Pharmacy has not surfaced active peptide-targeted enforcement.
Texas
Among the more permissive jurisdictions for peptide therapy. Multiple 503A compounding pharmacies operate openly. Texas Medical Board has not pursued the visible enforcement pattern that California has. Texas was an early adopter of broad telehealth authorization (SB 670, 2019).
All states · agency directory
The states below don't yet have a TPC editorial note. Each entry links to its state's medical and pharmacy board so you can verify the current rule directly with the regulator.
Email a link to the primary source (state statute, board meeting minutes, published enforcement letter) to [email protected]. We add cited entries, not rumored ones.